ATI Physical Therapy, Inc.: Nasdaq/NYSE listing notice — ATI Physical Therapy receives NYSE non-compliance notice due to low share price

ATI Physical Therapy, Inc.

NYSE notified ATI on Nov 18, 2022 that average closing price of ATIP was below $1.00 for 30 trading days.
Company has six months to regain compliance; may consider reverse stock split subject to stockholder approval.
Stock will trade under symbol ATIP with '.BC' designation indicating below compliance.
Non-compliance does not affect business operations or debt agreements.
If not cured, NYSE may initiate suspension and delisting procedures.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ATI Physical Therapy, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

Exchange: nyse
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 802.01C

Exact text from the filing

November 18, 2022, ATI Physical Therapy, Inc. (the “Company”), received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”), as the average closing price of the Company’s common stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001140361-22-043124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.